Mannkind Corp

NASDAQ: MNKD
$6.84
-$0.06 (-0.9%)
Closing Price on November 22, 2024

MNKD Articles

The short interest data are out for the April 29 settlement date, and short interest moves were mixed in these selected biotech stocks.
The most shorted of Nasdaq stock, Sirius XM, bucked the trend with a sharp increase in the number of its shares short.
The April 15 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
The largest decline among the top five most shorted Nasdaq stocks was in the shares of biopharmaceutical company MannKind. Intel’s short interest was essentially the same as at the end of March.
The March 31 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
The interest in the five most heavily shorted stocks traded on the Nasdaq declined between the March 15 and March 31 settlement dates. Leading that trend was AMD.
Interest in the most heavily shorted stocks traded on the Nasdaq rose, for the most part, between the February 29 and March 15 settlement dates. Leading that trend was Intel.
The February 29 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Many of the most heavily shorted stocks traded on the Nasdaq saw their short interest dwindle between the February 12 and February 29 settlement dates. Yet a few stocks bucked that trend.
The February 12 short interest data have been compared with the previous report, and short interest increased across the board in these selected biotech stocks.
When it came to the most heavily shorted stocks traded on the Nasdaq, short sellers appeared to be remain cautious.
The January 29 short interest data have been compared with the previous report, and short interest was mixed in most of the selected biotech stocks.
Bucking the short interest trend in late January were Frontier Communications, MannKind and Groupon.
24/7 Wall St. has evaluated the first formal short interest stocks of 2016 with a key eye on the companies in which a massive portion of their float is counted in the short interest.
Short interest increased in most of these selected biotech stocks for the most recent settlement date.